Detailed Closure Ages by Bone Region
All ranges represent the typical 10th–90th percentile window. Individual variation of ±2–3 years exists. Sources: Greulich-Pyle (1959) and Flecker (1942). ★ = height-contributing bone.
Hand & Wrist
First to fuse. Used for bone-age X-ray because closure sequence is well-mapped.
| Bone | Female | Male |
|---|---|---|
| Distal phalanges (fingertips) | 12–14 | 14–16 |
| Middle phalanges | 13–15 | 15–17 |
| Proximal phalanges | 13–15 | 15–17 |
| Metacarpals | 13–15 | 15–17 |
| Distal radius / ulna | 14–16 | 16–18 |
Arm
Upper arm bones fuse after the forearm.
| Bone | Female | Male |
|---|---|---|
| Olecranon (elbow) | 14–16 | 16–18 |
| Distal humerus | 13–15 | 15–17 |
| Proximal humerus (shoulder) | 15–17 | 17–19 |
Foot & Ankle
Similar timing to hand. Earlier fusion than long bones.
| Bone | Female | Male |
|---|---|---|
| Metatarsals & phalanges | 12–15 | 14–17 |
| Distal fibula | 14–16 | 16–18 |
| Distal tibia | 14–16 | 16–18 |
Knee & Leg (Height-Critical)
Femur and tibia are the primary height-determining bones. ★ marks height-critical.
| Bone | Female | Male |
|---|---|---|
| Distal femur ★ | 15–17 | 17–19 |
| Proximal tibia ★ | 15–17 | 17–19 |
| Proximal fibula | 14–16 | 16–18 |
| Proximal femur (hip) | 15–17 | 17–19 |
Spine
Vertebral ring apophyses are the last height-contributing plates. Small contribution to trunk height.
| Bone | Female | Male |
|---|---|---|
| Vertebral ring apophyses ★ | 17–19 | 19–22 |
Clavicle (Collarbone)
Last plate to fuse in both sexes. Does not contribute to standing height.
| Bone | Female | Male |
|---|---|---|
| Medial clavicle (sternoclavicular) | 22–25 | 22–25 |
Why Do Males and Females Close at Different Ages?
The primary driver is estrogen. Growth plate closure is triggered when estrogen levels reach a threshold that causes chondrocyte (cartilage cell) senescence — the cells stop dividing and begin calcifying. Females reach this estrogen threshold earlier and at higher levels than males (Cutler, 1997).
In males, androgens (testosterone) must be converted to estrogen by the enzyme aromatase before they can act on growth plates. This conversion introduces a delay. The evidence is dramatic: males with congenital aromatase deficiency — who cannot convert testosterone to estrogen — continue growing well into their 20s and can reach extraordinary heights before eventually receiving estrogen therapy (Carani et al., 1997, NEJM).
The practical consequence: males have more total growth time, which combined with a higher peak growth velocity (~10 cm/yr vs. ~8–9 cm/yr in females), produces the average male-female height difference of approximately 13 cm (Tanner & Davies, 1985).
Peak Height Velocity: Males vs. Females
- PHV onset: ~age 11–12
- Peak rate: ~8–9 cm/year
- Growth decelerates: rapidly after menarche
- Most growth done by: ~16
- PHV onset: ~age 13–14
- Peak rate: ~9–10 cm/year
- Growth decelerates: ~2 years after PHV
- Most growth done by: ~18–19
PHV = peak height velocity. Source: Tanner & Davies (1985).
When to see a doctor
If puberty signs appear before age 8 in girls or 9 in boys (precocious puberty), or if either sex has not started puberty by age 13 (girls) or 14 (boys), a pediatric endocrinologist evaluation is appropriate. Early or delayed puberty shifts the entire closure timeline and can affect final height if not managed. These tables represent typical population ranges, not diagnoses.